LACHEN, Switzerland--(BUSINESS WIRE)--At the recent World Federation of Haemophilia's (WFH's) world congress in Buenos Aires, Argentina, Octapharma AG confidently sponsored a symposium entitled “Modern Treatment Options for von Willebrand Disease (VWD) and Haemophilia B – What are the Benefits for the Patients?”, which took place on July 12, 2010. It focused on the remarkable clinical results from the next-generation von Willebrand factor (VWF)/coagulation factor VIII (FVIII) concentrate, Wilate®, and how it better reflects the normal physiological condition as compared to conventional concentrates. This well-attended, highly educational symposium addressed the effective management of VWD with Wilate® in the setting of surgery, the outstanding biochemical and pharmacokinetic profile of Wilate® to improve treatment, monitoring and dosing, and gave insights into the linking of experiences with prophylaxis in VWD with haemophilia A and B.
